Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14971262 | 1.00 | GPR119 (0.48) | GPR119NR1H2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26543757 | 0.94 | GPR119 (0.45) | GPR119NR1H2JAK2JAK1HPGD | |
| SCHEMBL21128725 | 0.91 | GPR119 (0.50) | GPR119NR1H2JAK2JAK1HPGD | |
| SCHEMBL26098762 | 0.91 | GPR119 (0.53) | GPR119HPGD | |
| SCHEMBL26100517 | 0.91 | GPR119 (0.53) | GPR119HPGD | |
| SCHEMBL19717722 | 0.91 | GPR119 (0.50) | GPR119NR1H2JAK2JAK1HPGD | |
| SCHEMBL26099289 | 0.91 | GPR119 (0.53) | GPR119HPGD | |
| SCHEMBL4516507 | 0.90 | CHRNB2 (0.51) | GPR119NR1H2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21042226 | 0.90 | CHRNB2 (0.51) | GPR119NR1H2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16962806 | 0.90 | CHRNB2 (0.51) | GPR119NR1H2CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | GPR119 216/4885NR1H2 408/4885CHRNB2 3217/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | GPR119 216/4885NR1H2 408/4885CHRNB2 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.